Table 2.

Proportional hazards analysis of pulmonary function in 89 survivors of childhood hematologic malignancies who received allogeneic HSCT

Tests	% of Patients below predicted values		Risk Factors	P value	Hazard Ratio
	Pre-transplant	Post-transplant*
Obstructive values
FEV1/FVC	18.0%	22.5%	Male	0.048	2.1
FEV1	22.5%	36.0%	Respiratory event (<1yr after HSCT)	0.0007	3.226
FEF25%–75%	16.9%	49.4%	Respiratory event (<1yr after HSCT)	0.0074	2.703
			Peripheral blood product	0.029	2.489
			High risk group	0.042	1.786
			Older recipient age (years)	0.038	1.082
Air trapping values
RV	40.4%	28.1%
RV/TLC	23.6%	38.2%
FRC	20.2%	15.7%
Restrictive values
FVC	15.7%	39.3%	Peripheral blood product	0.027	2.716
			Respiratory event (<1yr after HSCT)	0.028	2.257
			Acute GVHD	0.034	1.942
TLC	12.4%	43.8%	Younger donor age (years)	0.0025	1.035
			Cytarabine use	0.031	0.463
Diffusion values
DLCOcorr	19.1%	64.0%	Respiratory problem (>1yr after HSCT)	<0.0001	8.065
			High risk group	0.0006	2.558
			Positive recipient CMV antibody	0.036	1.704
			Older recipient age (years)	0.0051	1.102
			Cytarabine use	0.0025	0.399

^*The post-transplant abnormal group does not include those who were also abrnormal pre-transplant.

CMV indicates cytomegalovirus; DLCO_corr, diffusion capacity corrected for hemoglobin; FEF_25–75%, forced mid-expiratory flow; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; FRC, functional residual capacity; GVHD, graft versus host disease; HSCT, hematopoietic stem cell transplantation; RV, residual volume; TLC, total lung capacity